Incyte (INCY) reported $1.05 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 19.5%. EPS of $1.16 for the same period compares to $0.64 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $1.01 billion, representing a surprise of +4.66%. The company delivered an EPS surprise of +14.85%, with the consensus EPS estimate being $1.01.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how Incyte performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Net product revenues- Pemazyre: $18.44 million compared to the $21.62 million average estimate based on nine analysts. The reported number represents a change of +4.3% year over year.
- Revenues- Product revenues: $922.27 million compared to the $876.70 million average estimate based on nine analysts. The reported number represents a change of +26.4% year over year.
- Net product revenues- Iclusig: $29.54 million compared to the $28.67 million average estimate based on nine analysts. The reported number represents a change of -2.6% year over year.
- Net product revenues- Minjuvi/ Monjuvi: $29.55 million versus the nine-analyst average estimate of $33.43 million. The reported number represents a year-over-year change of +23.8%.
- Net product revenues- Opzelura: $118.71 million versus the nine-analyst average estimate of $126.95 million. The reported number represents a year-over-year change of +38.5%.
- Net product revenues- Jakafi: $709.41 million versus $661.10 million estimated by nine analysts on average. Compared to the year-ago quarter, this number represents a +24.1% change.
- Net product revenues- Zynyz: $3.01 million compared to the $1.92 million average estimate based on nine analysts.
- Royalty revenues- Jakavi: $92.15 million versus $97.41 million estimated by eight analysts on average. Compared to the year-ago quarter, this number represents a +2.9% change.
- Revenues- Product royalty revenues: $130.62 million versus the eight-analyst average estimate of $139.49 million. The reported number represents a year-over-year change of +3.7%.
- Royalty revenues- Olumiant: $30.80 million compared to the $34.90 million average estimate based on eight analysts. The reported number represents a change of +0.7% year over year.
- Royalty revenues- Tabrecta: $6.41 million compared to the $5.93 million average estimate based on eight analysts. The reported number represents a change of +22.5% year over year.
View all Key Company Metrics for Incyte here>>>
Shares of Incyte have returned -1.7% over the past month versus the Zacks S&P 500 composite's -0.8% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Incyte Corporation (INCY): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
